Randomized clinical trials for evaluating flow diverters intended to treat brain aneurysms are a difficult due to recruitment and ethical challenges, but FDA should still require randomized trials to support approval, according to a panel of its experts.
Multiple flow diverters are coming through the development pipeline. (See Also see "Stroke Devices: Neurointerventional Solutions Gain Momentum" -...